TB Alliance

Name

TB Alliance

Legal name

Global Alliance for TB Drug Development Inc.

Website

https://tballiance.org

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Tuberculosis Drug Development

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Professional Organizations (81392)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

akta.pro secondary industries

Disease-Specific Global Initiatives (HIV/TB/Malaria/NTDs) (HLAJAOAE), Tuberculosis & Mycobacterial Diseases (HLAKAGAH)

Keywords

• Tuberculosis drug development
• Product development partnership
• Antimicrobial resistance therapeutics
• Infectious disease pharmaceuticals
• Global health drug discovery

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Not-for-profit / Mission-driven organization: TB Alliance is a not-for-profit Product Development Partnership (PDP) that does not generate revenue through traditional commercial means. The organization is funded by governments, foundations, and institutional donors to discover, develop and deliver TB drugs. As a not-for-profit, TB Alliance makes the products it develops available to those who need them through partnerships and access initiatives rather than commercial sales.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels10 records

Core offering

TB Alliance is a not-for-profit product development partnership that discovers, develops, and delivers new tuberculosis drug regimens. Its offerings include novel chemical entities (e.g., pretomanid), combination regimens (BPaL, BPaL/M, SPaL), pediatric fixed-dose combinations, and long-acting injectable formulations, made available at affordable not-for-profit pricing through manufacturer licensees and global procurement institutions. The organization also operates market access programs (LIFT-TB, PeerLINC, Fast Track the Cure) and digital tools (Upskill TB, Manage TB) to accelerate country adoption.

Product overview

TB Alliance operates as a not-for-profit product development partnership managing the largest pipeline of new TB drugs in history. Its portfolio spans Discovery (lead identification/optimization programs including Malate Synthetase Inhibitors, ClpC1, MmpL3 Inhibitors, RNA Polymerase Inhibitors), Clinical Development (Phase 1-4 trials including TBAJ-587, NC-009/SPaL, Telacebec/Q203), and Marketed Products (Pretomanid, BPaL/BPaL/M regimens, pediatric formulations). Beyond TB, TB Alliance develops treatments for related mycobacterial diseases including leprosy and Buruli ulcer. Access initiatives include LIFT-TB, PeerLINC Knowledge Hub, Fast Track the Cure, SLASH-TB, and digital tools like Upskill TB and Manage TB to accelerate global adoption of new TB treatments.

Differentiator

Problem solved

Functional benefit

Products and services

• Pretomanid Pretomanid is a new chemical entity (nitroimidazooxazine) developed by TB Alliance for treating drug-resistant tuberculosis in combination regimens. Approved by US FDA (2019), EU (2021), India DCGI (2020), and prequalified by WHO (2021). It is made available to governments and global health programs at affordable not-for-profit pricing.
• BPaL Regimen BPaL is a three-drug, all-oral, six-month regimen consisting of bedaquiline + pretomanid + linezolid for treating highly drug-resistant TB. FDA-approved for XDR-TB and treatment-intolerant MDR-TB with approximately 90% treatment success rates in clinical trials and real-world implementation.
• BPaL/M Regimen BPaL/M is a modified BPaL regimen with moxifloxacin for treating multiple forms of drug-resistant TB. Currently used in over 100 countries, saving lives and reducing healthcare costs, with treatment success rates above 90% in real-world implementation.
• SPaL Regimen (Sorfequiline + Pretomanid + Linezolid) Novel regimen featuring sorfequiline (TBAJ-876), a next-generation diarylquinoline, combined with pretomanid and linezolid. Phase 2 trial showed greater efficacy than standard treatment with potential to shorten TB therapy. Subsequent plans include Phase 3 trial and long-acting injectable development.
• Telacebec (Q203) Investigational drug being developed for treating multiple mycobacterial diseases including tuberculosis, leprosy, and Buruli ulcer. Phase 2 trial underway. Under collaboration with Novartis (for leprosy) and Lupin (for clinical development and commercialisation).
• TBAJ-587 Diarylquinoline compound in Phase 1 clinical trials. Lead candidate for long-acting injectable formulations demonstrating sustained systemic exposure for up to four months in animal models.
• Pediatric TB Medicines Child-friendly TB treatments in correct fixed-dose combinations of rifampicin, isoniazid, and pyrazinamide with palatable fruit flavors that quickly disperse in liquid. WHO prequalified and ordered by 137 countries, covering 99% of global pediatric TB notifications; nearly 3 million treatment courses delivered.
• Long-Acting Injectable TB Formulations Long-acting injectable formulations for TB drugs designed to maintain therapeutic drug levels for months from a single injection, potentially enabling one-shot cures for active and latent TB. Lead candidates include sorfequiline, pretomanid, and TBAJ-587.

Quantifiable outcome

• 2+ million people treated with BPaL/M in first 15 years following approval
• +8 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

18 partnerships are on record, tiered core and major.

• LupincoreStrategic or Co-development Partner · 2 February 2026Lupin partnered with TB Alliance for clinical development and commercialisation of investigational drug Telacebec (Q203) for treating multiple mycobacterial diseases including tuberculosis, leprosy, and Buruli ulcer. TB Alliance leads development process while Lupin supports global manufacturing, regulatory affairs, and supply chain operations to ensure global access.
• NovartiscoreStrategic or Co-development Partner · 21 January 2026Novartis and WHO renewed partnership to provide multidrug therapy for leprosy globally at no cost for another five years, with goal to treat one million more people by 2030. Additionally, Novartis announced collaboration with TB Alliance to develop potential next-generation leprosy treatment - the first innovation in the disease since multidrug therapy was introduced over 40 years ago. TB Alliance to provide scientific and strategic advice on development.
• Indonesian Ministry of HealthcoreStrategic or Co-development PartnerTB Alliance forged strategic partnership with Indonesian Ministry of Health in 2025 to advance treatment innovation in TB and other mycobacterial diseases.
• Fiocruz (Oswaldo Cruz Foundation)coreStrategic or Co-development PartnerPartnership with Fiocruz (through Farmanguinhos) to accelerate access to new and next-generation TB treatments.
• Asian Development BankcoreStrategic or Co-development PartnerStrategic partnership to strengthen health systems, expand access to quality TB care, and promote coordinated innovation to accelerate progress toward TB control and elimination.
• Johns Hopkins UniversitycoreStrategic or Co-development PartnerCollaborated on modeling exercise quantifying BPaL/M impact. JHU conducted research showing regimen will save 191k lives and $1.29B by 2034. Partnership for preclinical screening of potential drug combinations using predictive animal models.
• ViatriscoreChannel Partner/ Reseller/ DistributorManufacturing partner for pretomanid and TB Alliance products. Works to ensure consistent global supply of products at affordable prices.
• MacleodscoreChannel Partner/ Reseller/ DistributorManufacturing partner for pretomanid and child-friendly TB formulations. Helps ensure consistent global supply at affordable prices.
• Hongqi PharmaceuticalcoreChannel Partner/ Reseller/ DistributorManufacturing partner for TB Alliance products to ensure consistent global supply at affordable prices.
• Remington PharmaceuticalscoreChannel Partner/ Reseller/ DistributorManufacturing partner for TB Alliance products in Pakistan to ensure regional supply access.
• Stop TB Partnership Global Drug FacilitycoreChannel Partner/ Reseller/ DistributorGlobal procurement institution facilitating access to TB medicines. TB Alliance works with GDF to ensure countries can access new treatments.
• The Global FundcoreChannel Partner/ Reseller/ DistributorGlobal health financing institution supporting TB programs. Works with TB Alliance to ensure affordable access to new TB treatments through funding and procurement.
• World Health Organization (WHO)coreStrategic or Co-development PartnerWHO provides normative guidance, treatment guidelines, and prequalification for TB Alliance products. Updated guidelines in 2022 to allow programmatic implementation of treating DR-TB with pretomanid-containing regimens. Recognized BPaL/M rollout as example of effective new antibiotic introduction.
• Afrigen Biologics and VaccinescoreStrategic or Co-development PartnerJoined TB Alliance's Global TB Stakeholders as partner in mRNA technology and LMIC capacity strengthening initiatives.
• Desmond Tutu TB CentrecoreStrategic or Co-development PartnerJoined TB Alliance's Global TB Stakeholders. Partnership focuses on championing children in the fight against TB.
• Clinton Health Access InitiativemajorStrategic or Co-development PartnerGlobal health organization and TB Alliance partner for access initiatives. Rasha Hibri, former CFO, serves on TB Alliance Board.
• LIFT-TB PartnerscoreStrategic or Co-development PartnerLIFT-TB (Leveraging Innovation for Faster Treatment of Tuberculosis) initiative in partnership with International Tuberculosis Research Center, South Korea and KOICA. Supported introduction of BPaL/M across seven countries: Indonesia, Kyrgyzstan, Myanmar, Philippines, Ukraine, Uzbekistan, Vietnam.
• Fast Track the Cure PartnerscoreStrategic or Co-development PartnerCommunity engagement initiative with partners including ASPAT Peru, CEDAPS (Brazil), Dopasi Foundation (Pakistan), Nari Maitree (Bangladesh), REACH (India), and TB Network (Nigeria). Mobilizing communities in nine high-burden countries to raise awareness and facilitate access to new DR-TB treatments.

Scale indicators15 records

Recent moves2 records

Direct peers

• FIND (Foundation for Innovative New Diagnostics): FIND is a Geneva-based global health PDP accelerating the development and equitable access of diagnostic tests for poverty-related diseases including TB. It is closely comparable as a fellow global health product development partnership operating in the TB ecosystem with overlapping donors and partner network.
• PATH: PATH is a global nonprofit that advances equitable health innovation through cross-sector partnerships across vaccines, drugs, devices, and diagnostics. Shares the multi-disease global health product development mission, donor base, and access-driven delivery model used by TB Alliance.
• Medicines for Malaria Venture (MMV): MMV is a Swiss-based PDP specifically focused on discovering, developing, and delivering new antimalarial drugs—mirroring TB Alliance's mandate and PDP structure. Both organizations advance co-developed combination regimens through public-private partnerships and prioritize affordability/endemic-country access over commercial returns.
• International AIDS Vaccine Initiative (IAVI): IAVI is a nonprofit PDP focused on HIV vaccine and antibody R&D, sharing the same product development partnership model as TB Alliance and overlapping donor base (Gates, USAID, governments). It uses a similar distributed R&D approach, WHO prequalification pathway, and access-driven licensing strategy for global health products.
• Medicines Development for Global Health: An Australia-headquartered nonprofit pharmaceutical company that similarly develops, registers, and provides access to medicines for neglected diseases (moxidectin for river blindness). Shares the same 'not-for-profit developer' model, regulatory strategy, and focus on underserved populations that TB Alliance uses for tuberculosis.
• Drugs for Neglected Diseases initiative (DNDi): DNDi is the closest direct peer to TB Alliance—a not-for-profit Product Development Partnership that develops new treatments for neglected diseases (sleeping sickness, leishmaniasis, Chagas, pediatric HIV, hepatitis C, mycetoma) using the same PDP model with public/private partners and access-focused licensing. Both organizations share donor constituencies (Gates, Wellcome, MSF) and operate via distributed R&D networks with globally accessible pricing.

Others

• Clinton Health Access Initiative (CHAI): CHAI is a global health organization operating across HIV, TB, malaria, and other diseases that negotiates pricing, supplies medicines, and strengthens health systems in LMICs. CHAI works in a complementary, ecosystem-partner role with TB Alliance on access and pricing initiatives for pretomanid and BPaL/M regimens.
• Gavi, the Vaccine Alliance: Gavi is a public-private global health alliance accelerating equitable and sustainable access to vaccines in lower-income countries—an adjacent global health PDP-style organization. It co-funds and shapes the introduction of new products (potentially including TB vaccines under development) that affect the future demand for TB Alliance's drug regimens.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat1 record

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/tballiance
• LinkedInlinkedin.com/company/tb-alliance

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TB Alliance